Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $430 | $524 | $599 | $825 |
| G&A Expenses | $0 | $1,745 | $1,550 | $1,957 |
| SG&A Expenses | $1,599 | $1,745 | $1,550 | $1,957 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,029 | $2,270 | $2,149 | $2,782 |
| Operating Income | -$2,029 | -$2,270 | -$2,149 | -$2,782 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $36 | $23 | $0 | $0 |
| Pre-Tax Income | -$1,993 | -$2,246 | -$2,149 | -$2,782 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,993 | -$2,246 | -$2,149 | -$2,782 |
| % Margin | – | – | – | – |
| EPS | -1.23 | -1.89 | -2.14 | -3.27 |
| % Growth | 34.9% | 11.7% | 34.6% | – |
| EPS Diluted | -1.23 | -1.89 | -2.14 | -3.27 |
| Weighted Avg Shares Out | 1,626 | 1,190 | 1,002 | 852 |
| Weighted Avg Shares Out Dil | 1,626 | 1,190 | 1,002 | 852 |
| Supplemental Information | – | – | – | – |
| Interest Income | $35,911 | $23 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $2,149 | $2,782 |
| EBITDA | -$1,993 | -$2,270 | $0 | $0 |
| % Margin | – | – | – | – |